{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.91","value":"3.66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"description":"E0 was defined as the Baseline serum concentration of phosphate.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participant self-administered intermittent pemigatinib once daily (QD) or continuous pemigatinib QD or twice daily (BID). Intermittent dosing: participants self-administered oral pemigatinib 1/2/4 milligrams (mg), 6 mg, 9 mg, 13.5 mg, or 20 mg once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg, 13.5 mg, or 20 mg QD on Days 1 through 21 of each 21-day cycle in Part 1 or Part 2. Participants self-administered oral pemigatinib 7.5 mg or 10 mg BID on Days 1 through 21 of each 21-day cycle in Part 1.","id":"OG000","title":"Parts 1 and 2: Intermittent or Continuous Pemigatinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic/Pharmacodynamic (PK/PD) Population: all enrolled participants who had PK/PD data. The average serum concentration of phosphate on Cycle 1 Days 8 and 15 was chosen as a dependent variable for E-R analysis, which was independent of the intermittent dosing and continuous dosing regimens. Therefore, the intermittent dosing and continuous dosing groups from Parts 1 and 2 were combined into a single analysis group for E-R analysis.","reportingStatus":"POSTED","timeFrame":"predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles","title":"E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2","type":"PRIMARY","unitOfMeasure":"milligrams per deciliter (mg/dL)"}